NCT00554398View on ClinicalTrials.gov

Impact of MK-0518 (Raltegravir) Intensification on HIV-1 Viral Latency in Patients With Previous Complete Viral Suppression

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

May 31, 2009

Study Completion Date

September 30, 2009

Conditions

HIV Infections

Interventions

DRUG

MK-0518 400mg twice a day

Raltegravir, MK-0518

Trial Locations (3)

08916

Hospital Germans Trias i Pujol, Badalona

08025

Hospital de la Santa Creu i Sant Pau, Barcelona

08036

Hospital Clínic I Provinical de Barcelona, Barcelona

All Listed Sponsors

collaborator

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

OTHER

lead

Germans Trias i Pujol Hospital

OTHER

NCT00554398 - Impact of MK-0518 (Raltegravir) Intensification on HIV-1 Viral Latency in Patients With Previous Complete Viral Suppression | Biotech Hunter | Biotech Hunter